Medical Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
This article is part of Med Tech Outlook's Innovation Insights series featuring expert contributions nominated by our subscribers and reviewed by our editorial team.
It is important to understand that PMCF strategies are like fingerprints; there can be no identical PMCF activities as there can be no identical clinical gaps. Even among equivalent devices, differences in terms of available clinical evidence highlight the need for customized actions. At Evnia, our PMCF process takes into account the interactions between regulatory processes. We favour the development of PMCF strategies that do not only take into account a device’s clinical evaluation but also user requirements, design features and risk management. Remediation of the clinical gaps emerging from the clinical evaluation indeed precedes finalization of PMCF planning and guides the decision for optimal activities. But in Evnia, we don’t want to lose sight of the big picture, i.e., the inherent risks, potential design changes, the future extension of indications, the global regulatory needs of a device throughout its lifetime. PMCF activities are customized to address the device-specific needs (in terms of population, indications, clinical claims etc.), while taking into account the manufacturer’s resources and business-like limitations (or ambitions). When it comes to the generation of PMCF data, there is not ‘’one ring to rule them all’. This is why Evnia’s multifaceted approach and embedment of RWD in PMCF activities enables the continuum between patient safety and market surveillance. The growing use of real-world evidence (RWE) contributes to quantifiable outcomes and therefore fulfils Evnia’s primary goal - to improve access to care by enhancing diversity of monitored populations and promoting healthcare innovation. In practical terms, this means that a manufacturer has the potential to choose from a pool of four different, standardized activities, which can support stand-alone or simultaneous clinical development objectives.Our full-value-chain services are supported by a growing, multidisciplinary, multinational and multicultural team of in-house medical writers, medical doctors, usability, risk, and validation engineers, biostatisticians, biocompatibility experts, and regulatory affair executives. It is our team of experienced, dedicated professionals that enable the implementation of tailored, timely, and cost-effective solutions. Evnia’s ecosystem has been designed to operate under advanced project management techniques and functions within a thorough, step-by-step review system to meet both the manufacturers’ and Authorities’ requirements. Evnia team members are supported by project and documentation management tools, ensuring audit and inspection readiness. However, none of this would make a difference without our ‘’translation experts’’, that is, our team members who accompany manufacturers along their regulatory journey by proposing realistic solutions and alternative routes of regulatory action. When it comes to PMCF-related projects, the above competitive advantages are crucial for ensuring data integrity and protection.
Evnia’s primary goal is to improve access to care by enhancing the diversity of monitored populations and promoting healthcare innovation.
The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
